Cargando…
Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking
Burosumab, an FGF23 targeting monoclonal antibody, was approved by the FDA in 2018 for use in children and adults with X-linked hypophosphatemia (or XLH). While several clinical studies have demonstrated the long-term safety and efficacy of Burosumab, the molecular basis of FGF23-Burosumab interacti...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427789/ https://www.ncbi.nlm.nih.gov/pubmed/36042241 http://dx.doi.org/10.1038/s41598-022-18580-3 |